Meribank Biotech Co., Ltd (TPEX:4724)
Taiwan · Delayed Price · Currency is TWD 8.88
-0.44 (-4.72%)
Aug 26, 2026, 1:09 PM CST
Meribank Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 408.48 | 471.76 | 366.43 | 234.34 | 180.12 | 163.08 | |
Revenue Growth | -16.04% | 28.75% | 56.36% | 30.10% | 10.45% | -16.11% |
Cost of Revenue | 265.55 | 269.59 | 172.49 | 95.47 | 85.35 | 73.02 |
Gross Profit | 142.93 | 202.18 | 193.94 | 138.87 | 94.77 | 90.06 |
Selling, General & Admin | 217.17 | 218.24 | 244.72 | 221.9 | 179.2 | 165.88 |
Research & Development | 28.07 | 31.26 | 35.9 | 35.48 | 25.94 | 16.11 |
Operating Expenses | 248.61 | 254.96 | 281.84 | 261.23 | 204.55 | 187.27 |
Operating Income | -105.68 | -52.78 | -87.9 | -122.36 | -109.78 | -97.22 |
Interest Expense | -23.8 | -23.11 | -10.7 | -0.85 | -0.99 | -1.13 |
Interest & Investment Income | 3.5 | 2.55 | 2.53 | 1.86 | 1.27 | 0.48 |
Earnings From Equity Investments | -5.15 | -3.63 | -11.93 | -5.41 | -5.42 | -4.51 |
Other Non Operating Income (Expenses) | -3.35 | -3.71 | 11.18 | 2.48 | 11.69 | 2.98 |
EBT Excluding Unusual Items | -134.48 | -80.68 | -96.81 | -124.28 | -103.23 | -99.39 |
Impairment of Goodwill | -2.1 | -2.1 | - | -5.67 | - | - |
Gain (Loss) on Sale of Investments | -6.15 | -6.15 | -4.73 | - | - | 0.18 |
Other Unusual Items | - | - | - | - | - | 0.02 |
Pretax Income | -142.74 | -88.94 | -101.55 | -129.95 | -103.23 | -99.19 |
Income Tax Expense | -6.78 | -6.78 | -4.61 | -0.44 | -0.08 | - |
Earnings From Continuing Operations | -135.96 | -82.16 | -96.94 | -129.51 | -103.15 | -99.19 |
Minority Interest in Earnings | 0.88 | 0.7 | 2.23 | 4.16 | 1.01 | - |
Net Income | -135.08 | -81.47 | -94.71 | -125.35 | -102.13 | -99.19 |
Net Income to Common | -135.08 | -81.47 | -94.71 | -125.35 | -102.13 | -99.19 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 96 | 91 | 80 | 63 | 63 | 60 |
Shares Outstanding (Diluted) | 96 | 91 | 80 | 63 | 63 | 60 |
Shares Change | 9.70% | 14.85% | 26.54% | 0.11% | 4.07% | 14.52% |
EPS (Basic) | -1.41 | -0.89 | -1.19 | -1.99 | -1.63 | -1.64 |
EPS (Diluted) | -1.41 | -0.89 | -1.19 | -1.99 | -1.63 | -1.64 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 62.51 | 85.62 | -286.7 | -35.5 | -45.48 | -30.2 |
Free Cash Flow Per Share | 0.65 | 0.94 | -3.60 | -0.56 | -0.72 | -0.50 |
Gross Margin | 34.99% | 42.86% | 52.93% | 59.26% | 52.62% | 55.22% |
Operating Margin | -25.87% | -11.19% | -23.99% | -52.21% | -60.95% | -59.61% |
Profit Margin | -33.07% | -17.27% | -25.85% | -53.49% | -56.70% | -60.83% |
Free Cash Flow Margin | 15.30% | 18.15% | -78.24% | -15.15% | -25.25% | -18.52% |
EBITDA | -38.04 | 7.22 | -50.76 | -110.86 | -98.08 | -86.11 |
EBITDA Margin | -9.31% | 1.53% | -13.85% | -47.31% | -54.45% | -52.80% |
D&A For EBITDA | 67.64 | 60 | 37.14 | 11.49 | 11.7 | 11.11 |
EBIT | -105.68 | -52.78 | -87.9 | -122.36 | -109.78 | -97.22 |
EBIT Margin | -25.87% | -11.19% | -23.99% | -52.21% | -60.95% | -59.61% |